Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
